Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain
CompletedPhase 2NCT00961194
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Nowadays, available drugs cannot always produce pain relief in patients with neuropathic pain disease. It is believed that drugs acting as antagonists of the N-methyl-D-aspartic acid (NMDA) receptor may have been efficient in the treatment of neuropathic pain disorders. Ketamine is the only NMDA receptor antagonist commercially available in France. Ketamine is usually administered intravenously for surgical anesthesia. The intravenous administration of ketamine will be difficult to manage in the treatment of chronic neuropathic pain. Some trials using oral ketamine for the treatment of neuropathic pain were conducted but results were heterogeneous. This may be explained by the different range of ketamine doses tested. The aim of this clinical trial is to identify a safe and an efficient dose of orally administrated ketamine for the treatment of peripheral neuropathic pain. The clinical trial will be conducted in Toulouse Hospital, France. This study is a randomized, double-blind, placebo-controlled trial. The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).
Study details
- Official title
- Evaluation of the Analgesic Effect of Orally Administrated Ketamine in Peripheral Neuropathic Pain Disease: Comparison of Three Doses Versus Placebo.
- Conditions
- Interventions
- Sponsor
- University Hospital, Toulouse
- Start date
- 2009-03
- Primary completion
- 2013-09
- Sex
- All
- Age range
- from 30 Years to 90 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients must suffer from peripheral neuropathic chronic pain. * Pain score must be at least 40 mm in a VAS (reflecting pain intensity during the 7 days and the day before visit 1). * Patients in which pain is not satisfactory relieved by level 1, 2 or 3 analgesic drugs (associated or not with antidepressants or antiepileptic drugs). Patients treated with level 2 or 3 analgesic drugs must stop these treatments one week before and during ketamine treatment. * Patients must benefit from the French Social security system. * Patients must be able to complete the tests. * Patients must give a written informed consent. * Patients must be aged from 30 to 90 years. * Female fertile patients must use an efficient method of contraception. Exclusion Criteria: * Patients not suffering from peripheral neuropathic chronic pain. * Pain score is less than 40 mm in a VAS (reflecting pain intensity during the 7 days and the day before visit 1). * Patients not able to complete the tests. * Patients not able to stop level 2 or 3 analgesic drugs. * Patients in which ketamine is contraindicated: * Hypersensibility to one of the compounds of the ketamine syrup * Uncontrolled arterial hypertension * Recent cardio vascular accident * Severe cardiac problems * Drug abuse * Psychosis
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00961194